

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Andrews *et al.*

Application No. 10/550,499

Filed: January 10, 2007

Confirmation No. 8366

For: MODULATION OF CELL PHENOTYPE
BY INHIBITORY RNA

FILED VIA EFS

Examiner:

Art Unit: 1645

Attorney Reference No. 7730-71694-01

FILED VIA ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER

Submitted herewith for filing in the application referenced above are the following:

- Request for Corrected Official Filing Receipt
 - Copy of original Filing Receipt with correction (Exhibit A).
 - First page of published PCT/GB2004/001374 (Exhibit B).
- The Director is hereby authorized to charge any additional fees that may be required with this filing, or credit over-payment, to Deposit Account No. 02-4550.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Tanya M. Harding/
Tanya M. Harding, Ph.D.
Registration No. 42,630

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Andrews *et al.***Application No.** 10/550,499**Filed:** January 10, 2007**Confirmation No.** 8366**For:** MODULATION OF CELL PHENOTYPE BY
INHIBITORY RNA**FILED VIA EFS****Examiner:****Art Unit:** 1645**Attorney Reference No.** 7730-71694-01FILED VIA ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE**REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT**

Applicants received the official Filing Receipt for the application referenced above, a copy of which (with requested correction handwritten thereon) is attached as Exhibit A.

The following error appears on the Filing Receipt:

| ITEM IN ERROR | CORRECT INFORMATION |
|--|--|
| Applicant: Maryam Marin | Applicant: Maryam Matin |

Attached as Exhibit B is a copy of the cover page of the published PCT application, which has the correct spelling of the applicant.

Applicants request that the identified error be corrected and that a new official Filing Receipt be issued.

Please call the undersigned if any further information is required.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Tanya M. Harding/
Tanya M. Harding, Ph.D.
Registration No. 42,630



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
www.uspto.gov

| APPL NO. | FILING OR 371 (c) DATE | ART UNIT | FIL FEE REC'D | ATTY.DOCKET NO | DRAWINGS | TOT CLMS | IND CLMS |
|------------|---------------------------|----------|---------------|----------------|----------|----------|----------|
| 10/550,499 | 01/10/2007 | 1645 | 590 | 5585-71694-01 | 20 | 23 | 3 |

CONFIRMATION NO. 8366

24197
 KLARQUIST SPARKMAN, LLP
 121 SW SALMON STREET
 SUITE 1600
 PORTLAND, OR 97204

FILING RECEIPT



OC000000022050725

Date Mailed: 01/19/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Peter Andrews, Sheffield, UNITED KINGDOM;
 Paul Gokhale, Sheffield, UNITED KINGDOM;
 Jim Walsh, Sheffield, UNITED KINGDOM;
 Maryam Marin, Sheffield, UNITED KINGDOM; Maryam Matin

Power of Attorney: The patent practitioners associated with Customer Number 24197.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/GB04/01374 03/25/2004

Foreign Applications


UNITED KINGDOM 0307206.3 03/28/2003

If Required, Foreign Filing License Granted: 01/18/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/550,499**

Projected Publication Date: 04/26/2007

Non-Publication Request: No



Early Publication Request: No

**** SMALL ENTITY ****

Title

Modulation of cell phenotype by inhibitory rna

Preliminary Class

435

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The

date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number
WO 2004/085654 A2

(51) International Patent Classification⁷: C12N 15/63 (74) Agent: HARRISON GODDARD FOOTE; 31 St. Saviourgate, York YO1 8NQ (GB).

(21) International Application Number:
PCT/GB2004/001374

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 25 March 2004 (25.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:
0307206.3 28 March 2003 (28.03.2003) GB

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 2004/085654 A2

(54) Title: MODULATION OF CELL PHENOTYPE BY INHIBITORY RNA

(57) Abstract: We describe a method to inhibit cell division of hyperproliferative cells, typically cancer cells, by introducing inhibitory RNA (RNAi) into said cells to ablate mRNAs that encode polypeptides involved in cellular processes and including RNAi molecules and vectors including transcription cassettes encoding said RNAi molecules. By application of said RNAi molecules to cancers *in vivo* it is possible to effect a treatment whereby the cancer cells are killed or otherwise eliminated.

